Literature DB >> 51920

Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin.

K L Birnberger, R Rüdel, A Struppler.   

Abstract

Six patients with congenital myotonia and 4 patients with myotonic dystrophy have been examined clinically before and after the administration of N-propyl-ajmalin, an alkaloid frequently used as a cardiac antiarrhythmic drug. All patients but one reported a good to moderate improvement of their myotonic muscle stiffness. This was verified by measuring the time the patients needed to ascend a flight of stairs and by recording the speed of opening the hand. The amplitude of the compound muscle action potential decreased during repetitive nerve stimulation in myotonic patients. This decrease was not influenced by N-propyl-ajmalin. It seems to be due to the increased after-depolarization observed in myotonic fibres which causes partial inactivation of the Na-carrying system. From one patient a muscle biopsy was taken and intracellular potentials were measured with a microelectrode. Almost all muscle cells investigated showed myotonic activity which was completely abolished by addition of 10(-5) g/ml N-propyl-ajmalin to the bathing fluid. The development and duration of "warm-up" is illustrated and a possible electrophysiological basis is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51920     DOI: 10.1007/bf00316381

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

1.  Electron spin resonance studies of erythrocytes from patients with myotonic muscular dystrophy.

Authors:  D A Butterfield; D B Chesnut; A D Roses; S H Appel
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

2.  Mammalian skeletal muscle: reduced chloride conductance in drug-induced myotonia and induction of myotonia by low-chloride solution.

Authors:  R Rüdel; J Senges
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

3.  Effects of quinidine, procaine amide, and N-propyl-ajmaline on skeletal muscle.

Authors:  J Senges; R Rüdel; E Kuhn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

4.  Muscular paralysis in myotonia congenita.

Authors:  K Ricker; H M Meinck
Journal:  Eur Neurol       Date:  1972       Impact factor: 1.710

5.  Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo.

Authors:  T L Munsat
Journal:  Neurology       Date:  1967-04       Impact factor: 9.910

6.  Diphenylhydantoin and the cations and phosphates of electrically stimulated brain slices.

Authors:  P D Swanson; P Crane
Journal:  Neurology       Date:  1970-04       Impact factor: 9.910

7.  Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids.

Authors:  S H Bryant; A Morales-Aguilera
Journal:  J Physiol       Date:  1971-12       Impact factor: 5.182

8.  Protein kinase activity in erythrocyte ghosts of patients with myotonic muscular dystrophy.

Authors:  A D Roses; S H Appel
Journal:  Proc Natl Acad Sci U S A       Date:  1973-06       Impact factor: 11.205

9.  [Neurophysiological studies on the temporary paresis in myotonia congenita and dystrophia myotonica].

Authors:  K Ricker; H M Meinch; H Stumpf
Journal:  Z Neurol       Date:  1973-04-02

10.  Effect of diphenylhydantoin sodium (dilantin) on myocardial A-V potassium difference.

Authors:  R H Helfant; M A Ricciutti; B J Scherlag; A N Damato
Journal:  Am J Physiol       Date:  1968-04
View more
  8 in total

1.  Influence of extracellular potassium and intracellular pH on myotonia.

Authors:  K L Birnberger; M Klepzig
Journal:  J Neurol       Date:  1979       Impact factor: 4.849

2.  Improved therapy of myotonia with the lidocaine derivative tocainide.

Authors:  R Rüdel; R Dengler; K Ricker; A Haass; W Emser
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

3.  Sodium channel slow inactivation as a therapeutic target for myotonia congenita.

Authors:  Kevin R Novak; Jennifer Norman; Jacob R Mitchell; Martin J Pinter; Mark M Rich
Journal:  Ann Neurol       Date:  2015-01-09       Impact factor: 10.422

4.  Transient muscular weakness in severe recessive myotonia congenita. Improvement of isometric muscle force by drugs relieving myotomic stiffness.

Authors:  K Ricker; A Haass; G Hertel; H G Mertens
Journal:  J Neurol       Date:  1978-08-25       Impact factor: 4.849

5.  Myotonia not aggravated by cooling. Force and relaxation of the adductor pollicis in normal subjects and in myotonia as compared to paramyotonia.

Authors:  K Ricker; G Hertel; K Langscheid; G Stodieck
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

6.  Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert.

Authors:  U Mielke; A Haass; S Sen; W Schmidt
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

Review 7.  Drug treatment for myotonia.

Authors:  J Trip; G Drost; B G M van Engelen; C G Faber
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

8.  Impaired Wheel Running Exercise in CLC-1 Chloride Channel-Deficient Myotonic Mice.

Authors:  Erik van Lunteren; Michelle Moyer; Jessica Cooperrider; Jennifer Pollarine
Journal:  Front Physiol       Date:  2011-08-09       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.